Stock Monitor: Unity Biotechnology Post Earnings Reporting
LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On June 11, 2018, the Company announced that it has signed a partnership deal with Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Unity Biotechnology, Inc. (NASDAQ: UBX), which also belongs to the Healthcare sector as the Company Alexion Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alexion Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation and has the potential to treat a variety of central nervous system disorders.
Terms of the Deal
- Alexion will provide Complement Pharma with up to €14 million in milestone-dependent payments through Phase-1b development.
- The agreement also provides Alexion with the option to acquire Complement Pharma during the term of the agreement.
- Alexion and Complement Pharma will collaborate on the development program for CP010. Complement Pharma will be responsible for conducting preclinical and Phase-1 studies and for manufacturing CP010. The phased agreement extends through the completion of Phase-1b development.
Collaboration Provides Opportunity to Expand on Alexion's Two Decades of Complement Leadership
Commenting on the announcement, John Orloff, M.D., Executive VP and Head of Research & Development at Alexion, stated that the Company has been a pioneer in complement biology since the development of Soliris, the world's first complement inhibitor, which has demonstrated the significant impact that C5 inhibition can have on several diseases caused by uncontrolled complement activation.
John added that this collaboration provides an exciting opportunity to expand on the Company's more than two decades of complement expertise to potentially treat additional diseases by targeting C6, a different component of the complement system.
The Company also announced recently that its management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California on June 12, 2018.
CP010 is a humanized monoclonal antibody in preclinical development that binds to C6 in circulation to inhibit its function throughout the body by preventing MAC formation in both the periphery and the central nervous system. An end product of the activated complement cascade, MAC has been shown to play a role in neurodegeneration. CP010 has demonstrated C6 inhibition in vitro and in vivo; C6 inhibition prevents the formation of the MAC following complement activation which may allow treatment of a variety of central nervous system disorders.
About Complement Pharma
Headquartered in Amsterdam, Netherlands, Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system. With a focus on C6, Complement Pharma aims to fight neurodegeneration in indications like TBI, ALS, and MS.
About Alexion Pharmaceuticals, Inc.
Founded in 1992 and headquartered in New Haven, Connecticut, Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company's three highly innovative therapies treat patients with four severe and ultra-rare diseases.
Stock Performance Snapshot
June 12, 2018 - At Tuesday's closing bell, Alexion Pharma's stock slightly rose 0.75%, ending the trading session at $117.58.
Volume traded for the day: 1.33 million shares.
Stock performance in the previous six-month period – up 2.73%; and past twelve-month period – up 10.01%
After yesterday's close, Alexion Pharma's market cap was at $26.67 billion.
Price to Earnings (P/E) ratio was at 43.45.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia